Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema

The authors describe a novel case of a 48-year-old male with bilateral diabetic macular edema (DME) who underwent intravitreal injection (IVI) of brolucizumab in the left eye. At four weeks, the patient demonstrated a bilateral response by way of improvement in the best-corrected visual acuity (BCVA...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in ophthalmological medicine 2022-01, Vol.2022, p.3755249-4
Main Authors: Chakraborty, Somnath, Sheth, Jay Umed
Format: Article
Language:English
Subjects:
Case Report
Case reports
Diabetes
Diabetic retinopathy
Dropsy
Edema
Eyes & eyesight
Injections
Monoclonal antibodies
Ophthalmology
Pegaptanib
Permeability
Pharmacokinetics
Vascular endothelial growth factor
Visual impairment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The authors describe a novel case of a 48-year-old male with bilateral diabetic macular edema (DME) who underwent intravitreal injection (IVI) of brolucizumab in the left eye. At four weeks, the patient demonstrated a bilateral response by way of improvement in the best-corrected visual acuity (BCVA) and reduction in the central macular thickness (CMT) in both eyes. Further studies on the ocular and systemic assays of the brolucizumab molecule are warranted to evaluate its systemic escape and to better understand the pharmacokinetics behind the bilateral effect.
ISSN:2090-6722
2090-6730
DOI:10.1155/2022/3755249